On January 10, 2022, Black Diamond Therapeutics, Inc. announced that the US Food and Drug Administration had allowed its Investigational New Drug application for BDTX-1535. The company expects to initiate the Phase 1 study of BDTX-1535 in the first quarter of 2022 and expects to provide a clinical update in the second half of 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.24 USD | +3.65% |
|
+24.35% | +121.71% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+121.71% | 34Cr | |
+20.43% | 13TCr | |
+24.42% | 12TCr | |
+25.44% | 2.77TCr | |
-17.98% | 2.03TCr | |
-15.17% | 1.68TCr | |
-14.85% | 1.56TCr | |
+12.76% | 1.48TCr | |
-47.10% | 1.46TCr | |
+56.26% | 1.44TCr |
- Stock Market
- Equities
- BDTX Stock
- News Black Diamond Therapeutics, Inc.
- Black Diamond Therapeutics, Inc. Announces US Food and Drug Administration Allows its Investigational New Drug Application for BDTX-1535